Cullinan Therapeutics Inc.

CGEM · United States

Share price · CGEM

$9.01-11.83 (-56.77%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.1M (1.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when CGEM's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 4 Nov 2026-20.7%
  2. 2 Oct 2026+6.7%
  3. 24 Sep 2026-8.5%
  4. 23 Sep 2026-22.2%
  5. 11 Aug 2026+7.4%
  6. 22 Jun 2026+15.1%
  7. 4 Jun 2026-5.1%
  8. 26 May 2026+11.7%
  9. 12 May 2026+9.6%
  10. 4 May 2026+14.2%

Share of unusual movement by asset

For each asset, the share of CGEM's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Zipalertinib
events and moves
103%
CLN-049
events and moves
6shown from 8 days
CLN-978
events and moves
5shown from 8 days
Velinotamig (GR1803)
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—14%
Other company news (earnings, financing, releases naming no asset)—22%
Sessions with no dated event—62%

Assets

(4 total)
4Total Assets
0Approved
2Phase 3 / Filed
2Phase 1–2 / Early
5Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Phase 3
BCMA x CD3Multispecific antibody
Multiple Myeloma
Phase 3
EGFRSmall molecule
Non-Small Cell Lung Cancer
Phase 1/2
FLT3, CD3Multispecific antibody
Acute Myeloid Leukemia
Phase 1
CD19 x CD3Multispecific antibody
Systemic Lupus ErythematosusRheumatoid Arthritis

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(6 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
May 2027 (1)
Velinotamig (GR1803)Phase 2Multiple Myeloma
Est. primary completion 2027-05-12 · NCT06566547 · CT.gov ↗
What to watch
June 2027 (1)
Velinotamig (GR1803)Phase 1/2Systemic Lupus Erthematosus, Auto Immune Disease
Est. primary completion 2027-06-01 · NCT07348055 · CT.gov ↗
What to watch
July 2027 (1)
Velinotamig (GR1803)Phase 2Multiple Myleoma
Est. primary completion 2027-07-01 · NCT06952075 · CT.gov ↗
What to watch
2029 (3)
January 2029 (1)
Velinotamig (GR1803)Phase 1/2Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
Est. primary completion 2029-01 · NCT07738822 · CT.gov ↗
What to watch
March 2029 (1)
Velinotamig (GR1803)Phase 3Multiple Myeloma
Est. primary completion 2029-03 · NCT07452198 · CT.gov ↗
What to watch
December 2029 (1)
CLN-049Phase 1/2Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), TP53-mutated MDS and AML
Est. primary completion 2029-12-30 · NCT05143996 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(6)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

27 February 2027FDA action dateZipalertinibPDUFA target action date for zipalertinib NDA
US, FDA · FDA · Source ↗

Recent

12 November 2026Filing submittedZipalertinibTaiho completes the NDA for zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion NSCLC
US, FDA · Source ↗
12 August 2026Topline resultZipalertinibREZILIENT3 Phase 3 (NCT05973773): primary endpoint met
Cullinan Therapeutics and Taiho Oncology · Source ↗
28 April 2026Filing acceptedZipalertinibFDA accepts NDA for zipalertinib (previously treated EGFR ex20ins NSCLC)
US, FDA · Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics · Source ↗
January 2026Filing acceptedVelinotamig (GR1803)China's NMPA accepts the conditional marketing application for velinotamig, with priority review
CN, NMPA · Genrix Bio · Source ↗
28 January 2025Topline resultZipalertinibREZILIENT1 Phase 2b primary endpoint met

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$40M$88M+ $201M short-term inv.$49M-$43M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$44M$79M+ $256M short-term inv.—-$38M operating cash flowreport ↗
2026-Q1—$42M$75M+ $277M short-term inv.—-$46M operating cash flowreport ↗
2025-Q3—$42M$103M+ $229M short-term inv.$51M-$37M operating cash flowreport ↗
2025-Q2—$61M$73M+ $193M short-term inv.$70M-$58M operating cash flowreport ↗
2025-Q1—$41M$77M+ $227M short-term inv.$49M-$43M operating cash flowreport ↗
2024-Q3—$36M$102M+ $476M short-term inv.$41M-$34M operating cash flowreport ↗
2024-Q2—$36M$115M+ $547M short-term inv.$42M-$36M operating cash flowreport ↗
2024-Q1—$31M$74M+ $359M short-term inv.$37M-$38M operating cash flowreport ↗
2023-Q3—$34M$65M+ $402M short-term inv.$39M-$34M operating cash flowreport ↗
2023-Q2—$27M$142M+ $350M short-term inv.$32M-$31M operating cash flowreport ↗
2023-Q1—$52M$122M+ $269M short-term inv.$58M-$51M operating cash flowreport ↗
2022-Q3$0$20M$243M+ $333M short-term inv.$25M-$54M operating cash flowreport ↗
2022-Q2$0$26M$354M+ $257M short-term inv.—-$25M operating cash flowreport ↗
2022-Q1$0$25M$76M+ $239M short-term inv.$12M-$22M operating cash flowreport ↗
2021-Q3$0$13M$88M+ $233M short-term inv.$17M-$11M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$187M$88M+ $290M short-term inv.$55M-$176M operating cash flowreport ↗

Cullinan Therapeutics did not disclose revenue for 2025. R&D expenses were $187.4M, up 31.1% YoY, and cash and investments totaled $439.0M as of December 31, 2025. The company reported a full-year net loss attributable to Cullinan of $219.88M, including a fourth-quarter net loss of $50.7M.

Management expects cash runway into 2029 under its current operating plan. Initial CLN-978 data in SLE and RA are planned for Q2 2026, repeat dosing data in RA for Q3 2026, and initial Sjögren’s disease data for Q4 2026, with initial velinotamig autoimmune data also expected in Q4 2026. An H2 2026 CLN-049 dose-escalation update is planned, dose-expansion cohorts are expected to begin in Q2 2026, and a frontline AML combination study is planned to start in Q4 2026. Partner Taiho completed the rolling NDA submission for zipalertinib and enrollment of the REZILIENT3 frontline study, with top-line results expected by year-end 2026; Cullinan is eligible for $30M and up to $100M in U.S. regulatory milestones, plus a 50/50 U.S. profit share.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$143M$83M+ $316M short-term inv.$42M-$145M operating cash flowreport ↗
2023-FY—$148M$98M+ $369M short-term inv.$38M-$134M operating cash flowreport ↗
2022-FY$0$92M$156M+ $311M short-term inv.—-$127M operating cash flowreport ↗
2021-FY$19M$58M$60M+ $231M short-term inv.$16M-$43M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 29 sales ($2.6M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-05Michaelson Jennifer · Chief Scientific OfficerOption exercise3,805$4.30$16KForm 4
2026-11-05Michaelson Jennifer · Chief Scientific OfficerOpen-market sale4,000$12.36$49KForm 4
2026-11-05Michaelson Jennifer · Chief Scientific OfficerOption exercise (derivative)3,805——Form 4
2026-09-08Michaelson Jennifer · Chief Scientific OfficerOption exercise4,000$4.30$17KForm 4
2026-09-08Michaelson Jennifer · Chief Scientific OfficerOpen-market sale8,000$21.57$173KForm 4
2026-09-08Michaelson Jennifer · Chief Scientific OfficerOption exercise (derivative)4,000——Form 4
2026-08-13Michaelson Jennifer · Chief Scientific OfficerOption exercise30,000$4.30$129KForm 4
2026-08-13Michaelson Jennifer · Chief Scientific OfficerOpen-market sale30,000$20.26$608KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 173 reporting institutions held 65.6M shares ($899.2M, 101.0% of shares outstanding).

#InstitutionSharesValue
1Lynx1 Capital Management LP8,963,500$127.4M
2MPM BIOIMPACT LLC7,648,268$108.7M
3BVF INC/IL5,750,683$81.7M
4BlackRock, Inc.4,449,966$63.2M
5Kynam Capital Management, LP3,114,132$44.3M
6STATE STREET CORP2,544,115$36.2M
7VANGUARD CAPITAL MANAGEMENT LLC2,483,034$35.3M
8Blue Owl Capital Holdings LP1,909,764$27.1M
9RTW INVESTMENTS, LP1,705,960$24.2M
10Venrock Adviser, LLC1,379,965$19.6M
11GEODE CAPITAL MANAGEMENT, LLC1,368,268$19.4M
12Siren, L.L.C.1,193,410$17.0M
13Nextech Invest, Ltd.1,141,145$16.2M
14BOOTHBAY FUND MANAGEMENT, LLC1,112,803$15.8M
15MARSHALL WACE, LLP1,049,581$14.9M